Back to results
US 12,569,552 B2Granted
Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein
AssigneeKM Biologics Co., Ltd.
InventorsMasaharu Torikai, Hiroaki Mori, Kohsuke Hazeyama, Miyuki Matsumoto
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide an effective vaccine that can prevent and treat infection with CMV. A fusion protein of the present invention is a fusion protein of envelope glycoprotein B (gB protein) and a pentamer of the cytomegalovirus (CMV). A vaccine for prevent or treat infection with cytomegalovirus (CMV) of the present invention is a subunit vaccine containing a fusion protein of envelope glycoprotein B (gB protein) and a pentamer of CMV as an antigen.
Claims23
A fusion protein complex comprising:
- three envelope glycoprotein B (gB proteins), and
- a pentamer of cytomegalovirus (CMV) proteins,
- wherein the fusion protein complex comprises three gB protein-CMV protein fusion proteins in which each of the three gB proteins is fused to a different CMV protein of the pentamer,
- wherein the gB protein is an ectodomain of a gB protein having 90% or more sequence identity with an ectodomain of the gB protein consisting of the amino acid sequence set forth in SEQ ID NO:
- 15, SEQ ID NO:
- 16, SEQ ID NO:
- 3, or SEQ ID NO:
- 31, and
- wherein the pentamer consists of the following CMV proteins:
- a gH protein comprising a sequence having 90% or more sequence identity with SEQ ID NO:
- 4;
- a gL protein comprising a sequence having 90% or more sequence identity with SEQ ID NO:
- 5;
- a UL128 protein comprising a sequence having 90% or more sequence identity with SEQ ID NO:
- 6;
- a UL130 protein comprising a sequence having 90% or more sequence identity with SEQ ID NO:
- 7;
- and
- a UL131 protein comprising a sequence having 90% or more sequence identity with SEQ ID NO:
- 8.
17 more elements
Dependencies are inferred from the claim text.